Aldeyra Therapeutics, Inc. Stock

$4.65

3.13% day before yesterday

Nasdaq, Jul 11, 10:13 pm CET

ISIN

US01438T1060

Symbol

ALDX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Aldeyra Therapeutics, Inc. Stock price

$4.65

-0.05 1.06% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-0.15 3.13%

ISIN

US01438T1060

Symbol

ALDX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$278.5m

Enterprise Value

$203.6m

Net debt

positive

Cash

$90.1m

Shares outstanding

60.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 9.8

EV/Sales

- | 7.2

EV/FCF

negative

P/B

4.4

Financial Health

Equity Ratio

67.9%

Return on Equity

-78.7%

ROCE

-77.5%

ROIC

Debt/Equity

0.2

Financials (TTM | estimate)

Revenue

$0.0 | $28.3m

EBITDA

$-60.9m | $-54.9m

EBIT

$-61.2m | $-48.5m

Net Income

$-57.7m | $-32.3m

Free Cash Flow

$-45.7m

EPS

$-1.0

FCF per Share

$-0.8

Short interest

7.7%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Aldeyra Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Aldeyra Therapeutics, Inc. forecast:

11x Buy

92%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Aldeyra Therapeutics, Inc. forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Aldeyra Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	12 12	6% 6% -
- Research and Development Expense	49 49	103% 103% -
EBITDA	-61 -61	73% 73% -
- Depreciation and Amortization	0.25 0.25	0% 0% -
EBIT (Operating Income) EBIT	-61 -61	73% 73% -
Net Profit	-58 -58	92% 92% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aldeyra Therapeutics, Inc. Stock News

Positive

Seeking Alpha

●

11 days ago

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Aldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for December 2025. After that, AbbVie may pay $100 million upfront and share US profits if Reproxalap wins approval, which should materially de-risk its eventual commercialization.

Neutral

Business Wire

●

17 days ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced receipt of a Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration (FDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently la...

Neutral

Business Wire

●

26 days ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new dr...

More Aldeyra Therapeutics, Inc. News

Company Profile

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Head office	United States
CEO	Todd Brady
Employees	9
Founded	2004
Website	www.aldeyra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now